GLAUrious SIGNED
External Automatic Glaucoma Laser (EAGLE) for the first-line glaucoma treatment: Commercial prototype development and validation
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0GLAUrious project word cloud
Explore the words cloud of the GLAUrious project. It provides you a very rough idea of what is the project "GLAUrious" about.
Project "GLAUrious" data sheet
The following table provides information about the project.
| Coordinator |
THE QUEEN'S UNIVERSITY OF BELFAST
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Project website | http://www.glaurious.eu |
| Total cost | 4˙036˙138 € |
| EC max contribution | 2˙480˙275 € (61%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2. (PRIORITY 'Industrial leadership') |
| Code Call | H2020-FTIPilot-2015-1 |
| Funding Scheme | IA |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-09-01 to 2020-02-29 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | THE QUEEN'S UNIVERSITY OF BELFAST | UK (BELFAST) | coordinator | 261˙791.00 |
| 2 | BELKIN LASER LTD | IL (YAVNE) | participant | 1˙575˙658.00 |
| 3 | UNIVERSITA DEGLI STUDI DI GENOVA | IT (GENOVA) | participant | 264˙682.00 |
| 4 | MAZO VSEVOLOD | DE (FRIEDRICHSDORF) | participant | 190˙894.00 |
| 5 | MEDICAL CONSULTING AND INVESTMENT | BE (MELSELE) | participant | 187˙250.00 |
Map
Project objective
The GLAUrious project is promoting the novel External Automatic Glaucoma Laser (EAGLE) device with the goal of providing accessible first-line treatment for glaucoma. Glaucoma, a chronic disease causing progressive optic nerve degeneration, is the leading cause of irreversible blindness globally. Although incurable, disease progression is delayed by reducing intraocular pressure, thus preventing blindness. Some 64 million people worldwide suffer from glaucoma. Current first-line treatment requires daily eye drops, a strict regimen causing 50% patient dropout after 1 year. Laser treatment for glaucoma has been in use for many years. Its effect lasts for 2−5 years and is repeatable. This traditional 10-minute procedure, involving contact with the patient’s eye, requires the expertise of glaucoma specialists. Consequently, costs are high and accessibility to the general population is low. The novel EAGLE procedure is automated, non-invasive, non-contact, painless and user friendly—1 second of treatment by one press of a button. This revolutionary cost-effective device could be safely used by the world’s 212,000 ophthalmologists, thus becoming a primary treatment for glaucoma, overcoming serious problems of eye drop non-compliance and effectively preventing disease deterioration. GLAUrious project aims to ease commercialization of the EAGLE device by securing clinical prototype validation, streamlining commercial production, optimizing component costs, disseminating to key opinion leaders and distributors, and refining commercial strategy. Validation of EAGLE will allow its commercialization enabling penetration of the ophthalmic market and boosting of the industrial consortium partners (BEL and MCI). The multidisciplinary GLAUrious Consortium, with its four partners from three member states (Belgium, Italy, UK) and one associated state (Israel), incorporates two SMEs and two academic hospitals.
Deliverables
| Report on study initiation and training of clinical sites | Documents, reports | 2020-01-23 08:41:31 |
| Interim report 1 of patients\' recruitment, study implementation and clinical trial monitoring | Documents, reports | 2020-01-23 08:41:31 |
| Quality control plan | Documents, reports | 2020-01-23 08:41:31 |
| Demonstrational prototypes produced | Demonstrators, pilots, prototypes | 2020-01-23 08:41:31 |
| Finalized clinical protocol and investigator brochure submitted | Documents, reports | 2020-01-23 08:41:31 |
| Report on planned communication activities | Documents, reports | 2020-01-23 08:41:31 |
| Updates to the risk mitigation strategy | Documents, reports | 2020-01-23 08:41:31 |
| Public website | Websites, patent fillings, videos etc. | 2020-01-23 08:41:31 |
Take a look to the deliverables list in detail: detailed list of GLAUrious deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLAURIOUS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLAURIOUS" are provided by the European Opendata Portal: CORDIS opendata.